All News
ICYMI: Sex bias in RA: time to stop blaming hormones?
Whether it’s RA, SLE or Sjogren’s, the increased prevalence of females affected by auto-immune diseases is well established, yet not fully understood. Often, I have heard that sexual hormones are responsible for every aspect of it. Two abstracts presented this year question this paradigm.
Read Article
ICYMI: Issues in AxSpA: Treatment Intensification, Pregnancy
A lot of interesting studies will be presented at the poster sessions on Sunday, November 12 and some of them address practical real-world issues such as treatment intensification and the impact of pregnancy on axSpA imaging.
Read Article
#RA pattern of synovitis is well knownn & decr in grip strength seen in Early (39%) & later RA (59% @5y). MCP1 synovitis impacts grip strength most (60%) followed by MCP4 (much less w/ tender/swelling of PIPs,other MCPs). Based on study of 215 early RA pts https://t.co/rTFBHKlNGV https://t.co/zCVsTNuYWW
Dr. John Cush RheumNow ( View Tweet)
ARCTIC Rewind: Three-Year Data in RA
https://t.co/ls2e3LtlvK https://t.co/FtgSq713rc
Dr. John Cush RheumNow ( View Tweet)
Rheum Fellowship Slots Fill Up for 2024
The NRMP announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions.
https://t.co/wTwajHyal0 https://t.co/JpgDUmioQh
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today!
https://t.co/wuvDqE0Qe6 https://t.co/8XXcQUBK6G https://t.co/ISRYMVdRfr
Dr. John Cush RheumNow ( View Tweet)
What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/vYSNzWuPVW https://t.co/tde3Mh6Wij
Links:
Dr. John Cush RheumNow ( View Tweet)
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life.
https://t.co/2ecihSwGIV https://t.co/rAjHvlyMB8
Dr. John Cush RheumNow ( View Tweet)
WATCH: TMP SMX Prophylaxis in GPA
https://t.co/VEkGFUewjG https://t.co/HouepsLEuw https://t.co/r1kiXejFQn
Dr. John Cush RheumNow ( View Tweet)
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
https://t.co/STybvwt9N5 https://t.co/BTwstJiFHr https://t.co/vfb2A5zZAp
Dr. John Cush RheumNow ( View Tweet)
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset?
https://t.co/eezZkBr8x7 https://t.co/D0dTSkjsNS https://t.co/nBlFyKNkHM
Dr. John Cush RheumNow ( View Tweet)
Can Rheumatologists Accurately Diagnose axSpA in Patients w/Chronic Back Pain?
Chronic low back pain is a common complaint that patients bring to the doctor’s attention.
https://t.co/dnlRtjsUHl https://t.co/wQq1J4Iudf https://t.co/24dQSWlwdr
Links:
Dr. John Cush RheumNow ( View Tweet)
"Protein kinases: drug targets for immunological disorders". Great full-read review from J Shea et al. Reviews Hx, biology, clinical use and safetey of Kinase targeted therapy. https://t.co/T4qMZG2DLI https://t.co/xANcLeiGr6 https://t.co/wAknXuvjl4
Dr. John Cush RheumNow ( View Tweet)
Check out this engaging video exploring the pathophysiology and management of gout flares. https://t.co/wgxUIkdJ7v https://t.co/kWRGXfPeYz
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today!
https://t.co/DSyFGlEJZx https://t.co/T0QoRCn3tK
Links:
Dr. John Cush RheumNow ( View Tweet)
PR3+ in Lupus Nephritis
https://t.co/rLdlAQYCfT https://t.co/CzLotVPwlh
Dr. John Cush RheumNow ( View Tweet)
Check out this engaging video exploring the pathophysiology and management of gout flares. https://t.co/LNmXZyDec1 https://t.co/nKojprg9mU
Dr. John Cush RheumNow ( View Tweet)
Next generation JAK-inhibition strategies
As there are many JAK-inhibitors evaluated in clinical trials currently, how do you stand out?
https://t.co/Pm6cCK5ltN https://t.co/h9z3nku1gZ
Dr. John Cush RheumNow ( View Tweet)
UKs MHRA issued a safety alert #MTX maybe associated w/ photosensitivity. Based on Coroners death (by secondary infx) report assoc w/ photosensitivity Rxn in a MTX Rx pt. Warning is because this is not a well-known side effect https://t.co/Vbl9BYMMNC https://t.co/9SyYQMTXTl https://t.co/JNqvNieqrt
Links:
Dr. John Cush RheumNow ( View Tweet)
Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1
Dr. John Cush RheumNow ( View Tweet)